VVY — Vivoryon Therapeutics NV Share News
0.000.00%
Last trade - 00:00Brief: Vivoryon Therapeutics Says VIVIAD Phase 2B Study Does Not Meet Primary Endpoints
Brief: Vivoryon Reports Positive Outcome To Proceed With Alzheimer Drug Study
Jefferies starts Vivoryon at 'buy' on positive risk/reward from Alzheimer's pill
Brief: Vivoryon Therapeutics Announces Proposed Appointment Of Frank Weber As Chief Executive Officer
Brief: Vivoryon Shares Clinical Development Update Highlighting Progress Of N3pE-Amyloid-Targeting Small Molecule Varoglutamstat In Alzheimer’S Disease
Brief: Vivoryon Therapeutics Net Loss Narrows At EUR 5.1 Million
Brief: Vivoryon Therapeutics Completes Listing Of 2.1 Mln Shares
Brief: Vivoryon Therapeutics 9-Month Net Loss Widens To 18.9 Million Eurs
Brief: Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation For Phase 2B Study Of Varoglutamstat
Brief: Vivoryon Therapeutics Q3 License Revenues At EUR 10.8 Mln
Brief: Dgap-News Vivoryon Therapeutics N.V. Successful Relocation Of Vivoryon Shares Package
Germany's Probiodrug prices Amsterdam listing at up to 32 mln euros